E-2814: A Comprehensive Review of an Investigational Anti-Tau Antibody for Alzheimer's Disease

Abstract

E-2814 (Etalanetug) is an investigational humanized monoclonal IgG1 antibody developed by Eisai Co., Ltd., in collaboration with University College London, targeting the microtubile binding region (MTBR) of the tau protein. Its mechanism involves binding to the HVPGG epitope within the MTBR, aiming to inhibit tau seeding, prevent cell-to-cell propagation of pathogenic tau species, and facilitate their microglial clearance, thereby addressing a core neuropathology of Alzheimer's Disease (AD). Clinical development has progressed through Phase 1 studies in healthy volunteers and Phase 1b/2 studies in patients with Dominantly Inherited Alzheimer's Disease (DIAD). These early trials have demonstrated a generally manageable safety profile and evidence of central nervous system target engagement, with a CSF-to-serum ratio of approximately 0.2%. Pharmacodynamic studies in DIAD patients have shown significant reductions in CSF biomarkers of tau pathology, including MTBR-tau243 and p-tau217, and trends towards stabilization or reduction in tau PET signal, effects not observed in healthy volunteers, suggesting disease-specific activity. E-2814 is currently being evaluated in larger Phase 2/3 trials, notably the Tau NexGen study (NCT05269394) in DIAD and a Phase 2 study (NCT06602258) in sporadic early AD, often in combination with the anti-amyloid antibody lecanemab. These ongoing studies are critical for determining the clinical efficacy of E-2814 in slowing cognitive decline and further characterizing its long-term safety. The development program reflects a strategy of leveraging insights from DIAD to inform sporadic AD research and exploring combination therapies targeting multiple AD pathologies.

1. Introduction to E-2814

• 1.1. Overview: E-2814 as an Anti-Tau Therapeutic Antibody E-2814, also known by the synonym Etalanetug, is an investigational humanized monoclonal immunoglobulin G1 (IgG1) antibody.1 It is under development by Eisai Co., Ltd. as a potential disease-modifying therapy for tauopathies, with a significant focus on Alzheimer's Disease (AD).1 The core therapeutic strategy of E-2814 revolves around its ability to target the microtubule binding region (MTBR) of the tau protein.1 Tau pathology, primarily characterized by the accumulation of neurofibrillary tangles (NFTs) composed of hyperphosphorylated tau, is a defining neuropathological feature of AD and is strongly correlated with the severity of cognitive decline. The development of E-2814 as an anti-MTBR tau antibody positions it within a critical area of AD research aimed at mitigating one of the disease's principal drivers.
• 1.2. Rationale for Development in Alzheimer's Disease The rationale for developing E-2814 is rooted in the "tau propagation" hypothesis, which posits that pathological tau species spread throughout the brain in a prion-like manner, moving from one neuron to another through synaptically connected pathways.4 This propagation is believed to be driven by specific conformers of tau containing the MTBR, often referred to as "tau seeds," which induce misfolding and aggregation of normal tau in recipient cells, thereby spreading the pathology to brain regions essential for cognitive function.4 E-2814 is designed to intervene in this process by binding to extracellular tau, particularly these pathogenic seeds. This interaction is intended to prevent their uptake by healthy neurons (cell-to-cell propagation) and to mediate their clearance, potentially through microglial cells, the resident immune cells of the brain.1 By intercepting these extracellular tau species, E-2814 aims to halt or slow the progressive spread of tau pathology, thereby preserving neuronal integrity and, consequently, cognitive function. This therapeutic approach is distinct from but complementary to anti-amyloid strategies, addressing another key pathological cascade in AD. The precision in targeting the MTBR, a region critical for filament formation and propagation, suggests a focused mechanism aimed at disrupting the core of tauopathy progression.2
• 1.3. Developer and Key Collaborations E-2814 is being developed by the pharmaceutical company Eisai Co., Ltd..1 The foundational discovery of the antibody stems from a research collaboration between Eisai and University College London (UCL).5 A pivotal aspect of E-2814's clinical development, especially for the rare, genetically driven form of AD known as Dominantly Inherited Alzheimer's Disease (DIAD), involves a significant collaboration with the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU). The DIAN-TU, led by Washington University School of Medicine in St. Louis, provides a unique platform for studying investigational therapies in individuals who are genetically destined to develop AD, often at a younger age.1 This academic-industry partnership with UCL underscores the importance of collaborative efforts in early drug discovery, while the DIAN-TU collaboration offers an invaluable opportunity to assess E-2814's effects in a well-characterized population with a predictable disease trajectory, which can yield crucial insights for both DIAD and the more common sporadic form of AD. The investigation of E-2814 in both DIAD and sporadic AD, frequently as part of a combination regimen with an anti-amyloid agent like lecanemab, reflects Eisai's comprehensive strategy. This dual approach acknowledges the multifaceted nature of AD pathology and the potential necessity of targeting multiple disease mechanisms, while also considering the critical variables of intervention timing and distinct patient populations.

2. Mechanism of Action

• 2.1. Targeting Tau Pathology: The Microtubule Binding Region (MTBR) E-2814 is engineered to specifically target the Microtubule Binding Region (MTBR) of the tau protein.1 The MTBR is a domain of tau that is not only crucial for its normal physiological function of stabilizing microtubules but is also intrinsically involved in the pathological aggregation of tau into filaments, which are the primary constituents of NFTs in AD.2 The epitopes recognized by E-2814 are located within the MTBR and are considered part of the core region of tau involved in the "seeding" process, where pathological tau templates the misfolding of normal tau.7 Targeting this specific region is intended to disrupt the fundamental processes that drive tauopathy.
• 2.2. Molecular Interaction: Binding to the HVPGG Epitope and Structural Details Detailed epitope mapping has identified that E-2814 recognizes and binds with high affinity to a specific linear sequence motif, 299-HVPGG-303 (Histidine-Valine-Proline-Glycine-Glycine), located within the MTBR of tau.1 High-resolution X-ray crystallography studies, achieving resolutions between 1.44 and 1.64 Å, have provided atomic-level insights into this interaction. These studies reveal that the core sequence for recognition by E-2814 is 299-HVPG-302, with an adjacent residue, Isoleucine 297 (I297) in the flanking N-terminal region, also contributing to the binding interface.2 The tau peptide, when bound, is accommodated within a recognition groove on the surface of the E-2814 Fab (Fragment, antigen-binding) fragment. This groove is formed by the Complementarity-Determining Regions (CDRs) of both the heavy chain (VH) and light chain (VL) variable domains of the antibody.2 A key structural feature of this interaction is that the bound tau peptide adopts a distinct U-shaped conformation, characterized by close-to quarter turns. The residues Histidine 299 (H299) and Proline 301 (P301), located at these turns within the tau peptide, are critical for mediating the major interactions with E-2814.2 This precise, structurally defined binding to a specific pathogenic epitope within the MTBR differentiates E-2814's mechanism, suggesting a focus on neutralizing the initial misfolding or seeding-competent conformations of tau, rather than merely binding to already formed, mature tangles. The induced U-shaped conformation of the tau epitope upon binding may be instrumental in neutralizing its pathogenic activity.
• 2.3. Proposed Effects: Inhibition of Tau Seeding, Propagation, and Clearance The therapeutic mechanism of E-2814 is predicated on its ability to interfere with the pathological cascade of tau. It is designed to prevent the spreading of "tau seeds"—pathogenic MTBR-containing tau species that drive the templated misfolding of normal tau—within the brain.4 By binding to these extracellular tau seeds, E-2814 aims to achieve several effects:

1. Inhibition of cell-to-cell propagation: Neutralizing extracellular tau seeds prevents their uptake by neighboring healthy neurons, thereby limiting the spread of tau pathology across neural networks.[1]
2. Mediation of clearance: It is proposed that E-2814, upon binding to tau seeds, facilitates their clearance from the extracellular space, potentially through uptake and degradation by microglial cells.[1] Collectively, these actions are intended to inhibit the aggregation of tau into NFTs and ultimately slow the cognitive decline associated with AD progression.[10] The involvement of microglia in the clearance of E-2814-bound tau seeds is an interesting aspect, suggesting a potential interplay with the brain's immune system. If this mechanism is significant, it could imply that the efficacy of E-2814 might be influenced by microglial function, potentially opening avenues for future therapeutic strategies that combine E-2814 with agents modulating microglial activity to enhance the clearance of pathogenic tau.

3. Clinical Development Program

• 3.1. Overview of Clinical Trials for E-2814 The clinical development of E-2814 has followed a structured path, beginning with initial safety and pharmacokinetic (PK) assessments in healthy volunteers, progressing to studies evaluating target engagement and biomarker effects in the genetically defined DIAD population, and now expanding into larger trials in both DIAD and sporadic early AD. A notable feature of the later-stage trials is the frequent inclusion of the anti-amyloid antibody lecanemab, reflecting an evolving understanding of AD as a multifaceted disease likely requiring combination therapies. The program aims to establish E-2814's safety and efficacy in modifying the course of tau pathology and, ultimately, clinical decline in AD. Table 1: Overview of Key Clinical Trials for E-2814

Trial ID	Study Identifier(s)	Phase	Target Population/Condition	Intervention(s)	Primary Objectives	Current Status (as of latest relevant snippet)
NCT04231513	E2814-G000-001	Phase 1	Healthy Volunteers	E2814 (IV, single and multiple ascending doses), Placebo	Assess safety, tolerability, PK, immunogenicity, pharmacodynamics (CSF target engagement)	Completed 3
NCT04971733	E2814-G000-103	Phase 1b/2	Mild to Moderate Cognitive Impairment due to DIAD	E2814 (IV, escalating doses)	Assess safety, tolerability, target engagement of E2814 with MTBR-tau in CSF, pharmacodynamics on AD tau biomarkers	Completed 12
NCT05269394	DIAN-TU-001 Tau Platform (Tau NexGen)	Phase 2/3	Presymptomatic and Symptomatic DIAD	E2814 (IV), Placebo, Lecanemab (background)	Slowing of tau accumulation (tau PET) in symptomatic participants; change in CSF p-tau217 in presymptomatic. Evaluate effects on cognitive decline if initial endpoints met.	Active, Not Recruiting 12
NCT06602258	E2814-G000-202	Phase 2	Early AD (MCI due to AD or mild AD dementia)	E2814 (IV, dose exploration), Placebo, Lecanemab (concurrent backbone)	Determine dose response of E2814 on change from baseline in CSF MTBR-tau-243 at 18 months. Evaluate safety, tolerability, biomarker efficacy.	Recruiting 4

*Data derived from multiple sources including.[1, 3, 4, 5, 8, 9, 10, 11, 12, 13, 14, 15, 16, 28, 32, 33]*

• 3.2. Phase 1 Study in Healthy Volunteers (E2814-G000-001 / NCT04231513) This foundational study was a randomized, double-blind, placebo-controlled trial involving single and multiple ascending doses of E-2814 administered intravenously to 72 healthy participants.3 Doses evaluated included 3 mg/kg, 10 mg/kg, and 30 mg/kg.1 The primary objectives were to assess the safety, tolerability, pharmacokinetics, immunogenicity, and CSF pharmacodynamics, specifically target engagement.3 Key safety findings indicated that E-2814 was safe and well-tolerated across the tested dose range, with no dose-limiting toxicities or significant drug-related clinical changes observed.1 The most frequently reported adverse events were headache, nausea, and vomiting.1 A single participant in the 30 mg/kg cohort experienced a transient, asymptomatic elevation in C-reactive protein.1 Pharmacokinetically, E-2814 demonstrated a dose-related increase in both serum and CSF exposure, achieving a CSF-to-serum concentration ratio of approximately 0.2%.3 Evidence of target engagement in the CSF was confirmed through concentration-related and sustained binding to MTBR-tau299 and MTBR-tau354, the antibody's epitopes.3 Critically, treatment with E-2814 did not alter levels of downstream tau pathology biomarkers, such as p-tau217 or MTBR-tau243, in these healthy volunteers.1 This lack of effect in a non-diseased state was an important early indicator supporting the hypothesis that E-2814's modulatory effects on tau pathology are specific to individuals with an active disease process.
• 3.3. Phase 1b/2 Study in Dominantly Inherited Alzheimer's Disease (DIAD) (E2814-G000-103 / NCT04971733) Following the healthy volunteer study, E-2814 was evaluated in an open-label, Phase 1b/2 study (E2814-G000-103; NCT04971733) involving participants with mild to moderate cognitive impairment due to DIAD.1 The primary goals were to assess safety, tolerability, and target engagement of E-2814 with MTBR-tau species in the CSF, alongside pharmacodynamic evaluations using a panel of AD-related tau pathology biomarkers.4 Approximately 8 participants were planned for enrollment, with results reported for 7 DIAD patients.7 These individuals had confirmed DIAD-causing mutations (in PSEN1, APP, or PSEN2), a Clinical Dementia Rating-Sum of Boxes (CDR-SB) score between 5 and 12, and confirmed amyloid positivity.1 Participants received E-2814 via intravenous infusion every 4 weeks, with doses escalating sequentially from 750 mg, 1500 mg, 3000 mg, to 4500 mg (minimum of three doses per dose level). After the escalation phase, participants were maintained on 4500 mg, with treatment durations reported between 12 to 24 months, and some data extending up to 108 weeks (26 months).1 This study, now completed 12, provided the first crucial data on E-2814's activity in an AD patient population. The DIAD cohort is particularly valuable due to the predictable age of onset and disease course, allowing for a clearer assessment of drug effects. The significant biomarker changes observed (detailed in Section 4) were pivotal for establishing proof-of-concept and for guiding the design of subsequent, larger clinical trials. The clinical development strategy, moving from healthy volunteers to this genetically defined AD population, allowed for a more controlled initial assessment of E-2814's biological effects before expanding to the more heterogeneous sporadic AD population.
• 3.4. Phase 2/3 Tau NexGen Study in DIAD (DIAN-TU-001 Tau Platform / NCT05269394) The Tau NexGen study (DIAN-TU-001; NCT05269394) is a significant Phase 2/3 platform trial conducted by the DIAN-TU, for which E-2814 was selected as the first anti-tau investigational drug.1 This trial aims to determine whether E-2814, and potentially other tau-targeting agents in separate arms, can affect key markers of tau pathology, such as tau phosphorylation and the formation of tau tangles, and ultimately slow or prevent the progression of AD in individuals with DIAD mutations.1 The study enrolls both presymptomatic and symptomatic DIAD participants.8 A key feature of the first arm of Tau NexGen is the evaluation of E-2814 in the context of background anti-amyloid therapy with lecanemab.1 The study employs a staggered intervention design:
• Symptomatic participants first receive lecanemab for six months, after which they are randomized to receive either E-2814 or placebo, in addition to continuing lecanemab.[1] This design is based on the premise that amyloid plaques accumulate before widespread tau tangles, and amyloid removal might create a more favorable environment for anti-tau therapies to exert their effects.
• Presymptomatic participants are randomized to receive either E-2814 or placebo for one year before lecanemab is introduced to both groups.[1] This allows for an assessment of E-2814's effects as a monotherapy in the very early, presymptomatic stages. The primary endpoint for symptomatic participants is the slowing of tau accumulation in the brain, as measured by tau PET imaging.[1] For presymptomatic participants, a key secondary endpoint is the change in CSF p-tau217 levels.[9] If these biomarker endpoints are met at the 2-year mark, the study is planned to be extended for an additional two years to assess longer-term effects on cognitive decline and tau pathology.[1] The Tau NexGen study was reported as active but not recruiting as of late 2022/mid-2023, with the first patient having been enrolled in January 2022.[1] This trial is pivotal, as its innovative design seeks to dissect the individual and combined contributions of anti-tau and anti-amyloid therapies and to understand the influence of intervention timing relative to symptom onset, potentially shaping future AD treatment paradigms.
• 3.5. Phase 2 Study in Sporadic Early Alzheimer's Disease (E2814-G000-202 / NCT06602258) To extend the investigation of E-2814 to the more common form of AD, Eisai initiated a Phase 2 study (E2814-G000-202; NCT06602258) in September 2024 for individuals with sporadic early AD.4 This is a placebo-controlled, double-blind, parallel-group, dose-exploration study designed to evaluate the safety, tolerability, and biomarker efficacy of E-2814 when administered concurrently with lecanemab as a backbone anti-Aβ therapy.4 The primary objective is to determine the dose-response of E-2814 (in combination with lecanemab) on the change from baseline at 18 months in CSF levels of MTBR-tau-243.14 The study aims to enroll approximately 90 participants aged 50-80 years with early AD, defined as MCI due to AD or mild AD dementia, confirmed amyloid pathology, and meeting specific cognitive (e.g., MMSE 22-30, CDR 0.5-1.0) and MRI criteria.14 Participants will receive either E-2814 or placebo in addition to lecanemab. The study is currently active and recruiting in the United States, with plans for expansion to Japan, and has an estimated completion date of August 2027.4 This trial is crucial for assessing whether the promising biomarker effects seen in DIAD patients translate to the broader sporadic AD population and for establishing an optimal dose of E-2814 in this context. The use of lecanemab as a standard backbone therapy is a significant design element, reflecting the potential future landscape where anti-amyloid treatments may be foundational, with anti-tau therapies providing additional benefit. The consistent inclusion of lecanemab in these later-stage E-2814 trials signals a strategic move towards evaluating combination therapies targeting both hallmark pathologies of AD simultaneously. While this may accelerate the demonstration of added clinical benefit if lecanemab provides a baseline improvement, it also introduces complexity in isolating the standalone clinical efficacy of E-2814. The DIAN-TU collaboration remains a cornerstone of E-2814's development, offering access to a highly valuable, genetically characterized cohort and a robust trial infrastructure, which accelerates research with implications far beyond this rare form of AD.

4. Pharmacodynamic Profile

• 4.1. Effects on Cerebrospinal Fluid (CSF) Tau Biomarkers (MTBR-tau243, p-tau217) The pharmacodynamic effects of E-2814 have been most notably characterized through changes in CSF tau biomarkers in the E2814-G000-103 study involving DIAD patients.1
• CSF MTBR-tau243: This biomarker, considered a fragment shed from established tau tangles and showing a strong correlation with tau PET imaging, exhibited significant reductions following E-2814 treatment. An approximate 50.6% decrease from baseline was observed after just 12 weeks of treatment (n=7).[1] This reduction was not only rapid but also sustained and deepened over time, reaching approximately 75% by the 2-year mark (n=2, with data up to 108 weeks).[4] It is noteworthy that E-2814 itself does not directly bind to the MTBR-tau243 fragment, nor does its presence interfere with the immunoassay used for its detection, suggesting the observed reduction reflects a genuine impact on tau pathology or its downstream products.[7]
• CSF p-tau217: Levels of p-tau217, a marker of tau hyperphosphorylation that is associated with both amyloid and tau PET signals (though more strongly with amyloid PET), also showed substantial decreases.[7] A reduction of 30.4% was seen after 12 weeks (n=7) [1], with this effect increasing to approximately 50% by 2 years (up to 57.9% reduction at 108 weeks, n=2).[1] Similar results were observed for the CSF pTau217/total tau217 ratio.[7] As with MTBR-tau243, E-2814 does not interfere with the p-tau217 assay.[7] In stark contrast, the E2814-G000-001 study in healthy volunteers showed no effect of E-2814 treatment on either MTBR-tau243 or p-tau217 levels after 12 weeks.[1] This divergence is critical, strongly indicating that E-2814's modulatory effects on these tau pathology biomarkers are disease-specific, occurring only in the presence of underlying AD pathology. The distinct responses of these biomarkers—MTBR-tau243 reflecting more mature tangle-related pathology and p-tau217 potentially earlier tau dysregulation linked to amyloid—suggest E-2814 might influence multiple stages or facets of the tau pathogenic cascade.
• 4.2. Impact on Tau PET Imaging Tau Positron Emission Tomography (PET) imaging provides a direct in vivo measure of fibrillar tau burden in the brain. In the E2814-G000-103 study with DIAD patients, E-2814 administration was associated with a stabilization or a trend towards a decrease in brain tau accumulation as observed by tau PET.4 More specific data from three DIAD patients who had tau PET scans at week 60 and week 108 indicated that one patient exhibited an overall 20% slowing of tau accumulation at week 60. By week 108, no further tau accumulation was observed via tau PET in any of these three individuals.1 However, an important consideration in interpreting these PET findings is the potential confounding effect of brain atrophy. Preliminary Partial Volume Correction (PVC) analysis on the Tau PET Standardized Uptake Value Ratio (SUVR) data suggested that approximately 60% of the observed SUVR reduction over time in these three patients could be explained by brain atrophy.7 While stabilization or reduction in tau PET signal is a highly encouraging outcome, the influence of atrophy highlights the complexity of interpreting imaging biomarkers in neurodegenerative diseases. It underscores the necessity for advanced analytical techniques like PVC and emphasizes that true therapeutic efficacy must translate to more than just an apparent signal reduction due to underlying tissue loss. Confirmation in larger studies with robust controls for atrophy will be essential.
• 4.3. Evidence of Target Engagement and Disease-Specific Effects Direct evidence of target engagement in the central nervous system (CNS) was demonstrated in both healthy volunteers (Study E2814-G000-001) and DIAD patients (Study E2814-G000-103). E-2814 administration led to concentration-related and sustained binding to its target epitopes within the MTBR of tau, specifically MTBR-tau299 and MTBR-tau354, in the CSF.3 This confirms that the antibody reaches the CNS at sufficient concentrations to interact with its intended molecular target. The most compelling evidence for disease-specific effects comes from the differential impact on downstream tau pathology biomarkers. As noted, significant reductions in CSF MTBR-tau243 and p-tau217 were observed in DIAD patients, whereas no such changes occurred in healthy volunteers treated with E-2814.1 This pattern strongly supports the hypothesis that E-2814's pharmacodynamic actions on tau pathology are contingent upon an active disease process and that the antibody may not interfere with normal tau physiology in individuals without AD pathology. Table 2: Summary of E-2814 Pharmacodynamic Effects on Tau Biomarkers in DIAD Patients (Study E2814-G000-103 / NCT04971733)

Biomarker	Measurement Timepoint	Observed Change/Effect	Patient Cohort (n)	Source(s)
CSF MTBR-tau243	12 weeks	~50.6% reduction	7	1
CSF MTBR-tau243	36 weeks	Most significant reduction (-71.6%)	4	1
CSF MTBR-tau243	Up to 108 weeks (2 years)	~75% reduction, sustained	2-7 (varies by time)	4
CSF p-tau217	12 weeks	30.4% reduction	7	1
CSF p-tau217	36 weeks	48.6% reduction	5	1
CSF p-tau217	Up to 108 weeks (2 years)	~50-57.9% reduction	2-7 (varies by time)	1
Tau PET SUVR	60 weeks	One patient showed 20% slowing of tau accumulation	3 (PET sub-study)	1
Tau PET SUVR	108 weeks	No tau accumulation observed; stabilization/trend to decrease	3 (PET sub-study)	1

*This table quantitatively summarizes the core evidence of E-2814's biological activity on key pathological markers of AD, providing a clear snapshot of its impact in the DIAD population. This is crucial for assessing proof-of-mechanism.*

5. Clinical Efficacy Data

• 5.1. Summary of Biomarker-Based Efficacy from Clinical Trials To date, the primary evidence supporting the potential efficacy of E-2814 is derived from its impact on biomarkers of tau pathology, as observed in clinical trials. The most significant findings stem from the E2814-G000-103 study in DIAD patients, which demonstrated substantial and sustained reductions in key CSF tau biomarkers, namely MTBR-tau243 and p-tau217.1 Additionally, tau PET imaging in a subset of these DIAD patients indicated a stabilization or a trend towards a decrease in brain tau accumulation.4 These biomarker changes are interpreted as suggestive evidence that E-2814 inhibits tau propagation and suppresses the accumulation of tau aggregates in the brain, consistent with its proposed mechanism of action.4 In the context of early-phase AD drug development, particularly for novel therapeutic mechanisms, such biomarker responses often serve as crucial initial indicators of biological activity and potential future clinical benefit, paving the way for larger, longer-duration trials designed to assess cognitive and functional outcomes.
• 5.2. Reported Clinical Outcomes (if any, e.g., cognitive measures) The early-phase clinical trials of E-2814, including the Phase 1 study in healthy volunteers (E2814-G000-001) and the Phase 1b/2 study in DIAD patients (E2814-G000-103), were primarily designed to evaluate safety, tolerability, pharmacokinetics, target engagement, and proof-of-mechanism through biomarker changes.1 Consequently, these studies were not powered to detect statistically significant effects on clinical outcomes such as cognitive decline or functional impairment. The available research snippets do not report specific cognitive or functional efficacy data for E-2814 from these completed early studies. The assessment of E-2814's impact on clinical progression is a key objective of the ongoing, larger clinical trials. The Phase 2/3 Tau NexGen study (NCT05269394) in DIAD patients is designed to evaluate effects on cognitive decline as a later endpoint, contingent upon meeting initial biomarker-based endpoints.1 Similarly, the Phase 2 Study 202 (NCT06602258) in sporadic early AD focuses primarily on safety, tolerability, and biomarker efficacy, with cognitive outcomes likely designated as secondary or exploratory at this stage of investigation.4 It is important to note that a quote found in some sources 1 mentioning "encouraging signals on several clinical end points," including gains in the 6-Minute Walk Test and SBMA Functional Rating Scale, refers to a different investigational drug, AJ201, and not E-2814. Therefore, currently, there is no direct clinical efficacy data (cognitive or functional improvements) reported for E-2814 within the provided research materials. The current lack of reported clinical efficacy data is consistent with the stage of E-2814's development, where the emphasis has been on establishing safety, confirming target engagement, and observing biomarker modulation in smaller, early-phase investigations. The definitive test of E-2814's ability to confer clinical benefit will emerge from the ongoing Phase 2/3 Tau NexGen trial and the Phase 2 study in sporadic AD. The strategy of incorporating lecanemab as a backbone therapy in these larger trials 1 may expedite the demonstration of E-2814's additive clinical benefit, assuming lecanemab itself provides a baseline level of amyloid-related clinical improvement. However, this approach also introduces challenges in dissecting the standalone clinical efficacy of E-2814, a question that could be pertinent for patient populations unable to receive anti-amyloid treatments. The design of the Tau NexGen presymptomatic arm, which includes a period of E-2814 or placebo monotherapy before the introduction of lecanemab 1, is an attempt to address this for early intervention scenarios.

6. Safety and Tolerability Profile

• 6.1. Adverse Events Observed in Healthy Volunteers (Study E2814-G000-001 / NCT04231513) In the Phase 1 study conducted in healthy volunteers, E-2814 was generally found to be safe and well-tolerated.1 No significant drug-related clinical changes or dose-limiting events were reported across the single and multiple ascending dose cohorts.1 The most commonly reported adverse events (AEs) associated with E-2814 administration were headache, nausea, and vomiting.1 One participant, who received a 30-mg/kg dose, experienced an asymptomatic elevation in C-reactive protein levels 2-3 days post-infusion, which subsequently resolved to baseline levels without intervention.1 Importantly, no infusion-related reactions or other clinically significant safety signals were observed with either single or repeated doses of E-2814 administered for up to 15 months in this population.3 These findings provided initial reassurance regarding the safety of E-2814 and supported its advancement into patient studies.
• 6.2. Adverse Events Observed in DIAD Patients (Study E2814-G000-103 / NCT04971733) In the Phase 1b/2 study involving DIAD patients, E-2814 was also reported to be generally safe and well-tolerated.7 However, the AE profile in this patient population included some serious adverse events (SAEs). Among the 7 DIAD participants, five discontinued the study for various reasons: two due to subject choice, one due to withdrawal of consent, one attributed to deterioration of their underlying condition, and one due to an adverse event, specifically recurrent Chronic Lymphocytic Leukemia (CLL).7 The relatedness of the CLL recurrence to E-2814 would require careful assessment, as it could be an intercurrent illness. Five SAEs were reported in three of the seven DIAD participants 7:
• One participant experienced cerebral venous sinus thrombosis and vaginal bleeding, which occurred in the context of a suspected gynecologic malignancy.
• Another participant reported a chest infection and a subsequent seizure, with the seizure considered secondary to the chest infection.
• A third participant reported arthritis. The difference in AE profiles between healthy volunteers (primarily mild AEs) and DIAD patients (some SAEs reported) could be attributable to several factors, including the underlying disease pathology in DIAD individuals, potentially longer exposure durations or higher cumulative doses in the patient study, or simply stochastic occurrences within a very small sample size. This highlights the necessity of evaluating investigational drugs directly within the target patient population.
• 6.3. Overall Tolerability Assessment Based on the cumulative data from the Phase 1 study in healthy volunteers and the Phase 1b/2 study in DIAD patients, E-2814 appears to possess a generally manageable safety profile.1 The types of adverse events observed are broadly consistent with those anticipated for monoclonal antibody therapies administered intravenously. However, the occurrence of SAEs in the small DIAD cohort, including vascular, infectious, and inflammatory events, underscores the need for diligent safety monitoring in the ongoing and future larger-scale clinical trials. The safety profile of E-2814 will be of particular importance in the context of its combination with lecanemab, as lecanemab itself carries known risks, most notably Amyloid-Related Imaging Abnormalities (ARIA). The potential for additive or synergistic toxicities when these two biologic agents are co-administered will be a critical area of evaluation in the ongoing combination trials (NCT05269394 and NCT06602258). Robust safety monitoring protocols are essential in these studies, especially given the often elderly and potentially vulnerable AD patient population. The current safety data support the continued development of E-2814, but ongoing vigilance and comprehensive data collection from larger trials are imperative for a full characterization of its risk-benefit profile. Table 3: Adverse Events Reported in E-2814 Clinical Trials

Study Population	Adverse Event Category	Specific Adverse Event	Incidence/Details	Seriousness	Source(s)
Healthy Volunteers	Common AEs	Headache, Nausea, Vomiting	Most commonly reported	Non-serious	1
Healthy Volunteers	Laboratory Abnormality	Elevated C-reactive protein	1 participant (30-mg/kg group), transient, asymptomatic, returned to baseline	Non-serious	1
Healthy Volunteers	General	No infusion-related reactions or clinically significant safety signals	Observed with single or repeated doses up to 15 months	N/A	3
DIAD Patients	Discontinuations	Subject choice, withdrawal of consent, deterioration of condition, AE (recurrent CLL)	5 of 7 participants discontinued for various reasons	Varied	7
DIAD Patients	Serious Adverse Events (SAEs)	Cerebral venous sinus thrombosis AND Vaginal bleeding	1 participant (in context of suspected gynecologic malignancy)	SAE	7
DIAD Patients	Serious Adverse Events (SAEs)	Chest infection AND Seizure	1 participant (seizure considered secondary to chest infection)	SAE	7
DIAD Patients	Serious Adverse Events (SAEs)	Arthritis	1 participant	SAE	7

*This table delineates safety observations, highlighting events of particular concern such as SAEs and reasons for discontinuation in the DIAD cohort.*

7. Pharmacokinetics (PK)

• 7.1. Serum and CSF Pharmacokinetics Pharmacokinetic assessments of E-2814 have been conducted in both healthy volunteers (Study E2814-G000-001) and DIAD patients (Study E2814-G000-103). In healthy volunteers, E-2814 demonstrated a dose-related increase in both serum and cerebrospinal fluid (CSF) exposure following intravenous administration.3 Notably, CSF concentrations of E-2814 were found to remain elevated for a prolonged period, specifically for 24 hours up to the last measured time-point of 672 hours (Day 29).8 The pharmacokinetic profile observed in DIAD patients appeared to be comparable to that seen in healthy participants.3 The demonstration of dose-proportional exposure and sustained presence in the CSF are critical attributes for a centrally-acting antibody, and the consistency between healthy and DIAD populations simplifies pharmacokinetic modeling and dose selection for further studies.
• 7.2. CSF-to-Serum Ratio and Target Engagement The penetration of E-2814 into the central nervous system, as indicated by the CSF-to-serum concentration ratio, was found to be approximately 0.2%.3 This level of CNS penetration is generally typical for monoclonal antibodies that cross the blood-brain barrier. Crucially, target engagement in the CSF was successfully demonstrated. E-2814 showed concentration-related and sustained binding to its specific tau epitopes, MTBR-tau299 and MTBR-tau354, in the CSF of both healthy volunteers and DIAD participants.3 This provides direct evidence that therapeutically relevant concentrations of E-2814 are reaching the CNS and interacting with its intended molecular targets within the tau protein. The sustained CSF concentrations and confirmed target engagement for up to 29 days lend pharmacokinetic support to the every 4 weeks (Q4W) dosing interval employed in the clinical trials of E-2814.1 While a CSF-to-serum ratio of ~0.2% is standard for mAbs, the actual free concentration of E-2814 available to bind pathological tau within the brain parenchyma (beyond just the CSF) and its efficacy in penetrating various affected brain regions remain important considerations for optimizing therapeutic outcomes.

8. Regulatory Status and Future Outlook

• 8.1. Current Investigational Status E-2814 is currently an investigational drug and has not received regulatory approval for general medical use in any jurisdiction. Access to E-2814 is limited to participation in formal clinical trials.4 The clinical development program is active and progressing:
• Phase 1 studies in healthy volunteers (NCT04231513 / E2814-G000-001) and the Phase 1b/2 study in DIAD patients (NCT04971733 / E2814-G000-103) have been completed.[12]
• A pivotal Phase 2/3 study in DIAD, known as the Tau NexGen trial (DIAN-TU-001 Tau Platform / NCT05269394), is ongoing. As of late 2022/mid-2023, this trial was reported as active but not currently recruiting new participants.[1]
• A Phase 2 study in sporadic early AD (NCT06602258 / E2814-G000-202), evaluating E-2814 in combination with lecanemab, is actively recruiting participants.[4]
• 8.2. Information on Regulatory Designations (e.g., Fast Track, Orphan Drug) Based on the provided research materials, there is no explicit information indicating that E-2814 itself has received specific regulatory designations such as Fast Track status from the U.S. Food and Drug Administration (FDA) or Orphan Drug Designation from either the FDA or the European Medicines Agency (EMA).3 While lecanemab, an anti-amyloid antibody often studied in conjunction with E-2814, has received such designations and approvals 20, similar information for E-2814 is not highlighted. The DIAN-TU, which leads the Tau NexGen study, does have established agreements with the FDA and EMA regarding the study's design 27, which may facilitate a streamlined development pathway for DIAD, a rare condition. However, specific designations for E-2814 are not mentioned. The absence of such information in the provided documents is noteworthy. It could imply that applications for these designations are pending, have not yet been made, or that the regulatory strategy is focused on the broader AD indication where such designations might be more challenging to obtain, especially if other anti-tau agents are also in development. The collaboration with DIAN-TU itself might offer an efficient development route through its established regulatory interactions.
• 8.3. Ongoing Research and Potential Role in Alzheimer's Disease Therapy The ongoing research for E-2814 is sharply focused on rigorously evaluating its efficacy in slowing cognitive decline and modifying the course of tau pathology in both DIAD and sporadic early AD populations. A central theme in this research is the assessment of E-2814 in combination with anti-amyloid therapy, primarily lecanemab.1 The innovative design of the Tau NexGen study, with its staggered administration of E-2814 and lecanemab, is specifically intended to dissect the individual and combined effects of anti-tau and anti-amyloid interventions, as well as the impact of treatment timing relative to symptom onset.1 If the ongoing trials yield positive results, E-2814 has the potential to become a significant component of future AD therapeutic regimens, specifically addressing the tau dimension of the disease's complex pathology.25 The promising biomarker data from DIAD studies has provided a strong rationale for its continued exploration in sporadic AD.3 Eisai continues to disseminate findings from its E-2814 program at major scientific conferences, such as the planned presentations on the clinical study design for its combination with lecanemab in sporadic early AD at the AD/PD 2025 conference.28 The regulatory strategy appears closely linked with the DIAN-TU network for DIAD and leverages the established anti-amyloid agent lecanemab for trials in sporadic AD, suggesting a pathway that may prioritize demonstrating an additive benefit in genetically or biomarker-defined populations. E-2814 represents a focused effort in the anti-tau field, and its development within sophisticated trial designs could pave the way for combination treatments that offer a more holistic approach to managing Alzheimer's disease.

9. Conclusion

E-2814 (Etalanetug) stands as a promising investigational anti-tau antibody, distinguished by its specific targeting of the HVPGG epitope within the MTBR of tau. Its proposed mechanism—inhibiting tau seeding, preventing intercellular propagation, and promoting microglial clearance—addresses a fundamental pathological process in Alzheimer's Disease. Early-phase clinical trials in healthy volunteers have established an initial safety profile and confirmed CNS target engagement. More significantly, studies in patients with DIAD (NCT04971733) have demonstrated compelling pharmacodynamic effects, with substantial reductions in CSF biomarkers MTBR-tau243 and p-tau217, and encouraging trends in tau PET imaging. These biomarker responses, which were not observed in healthy individuals, suggest a disease-specific action of E-2814.

The safety profile to date has been generally manageable, though SAEs observed in the small DIAD cohort warrant continued careful monitoring in larger trials. The pharmacokinetic data support the Q4W dosing regimen, showing adequate CNS penetration and sustained target engagement.

Currently, E-2814 is advancing through more definitive clinical trials. The Phase 2/3 Tau NexGen study (NCT05269394) in DIAD and the Phase 2 study in sporadic early AD (NCT06602258), both often incorporating the anti-amyloid agent lecanemab, are critical for determining its clinical efficacy in slowing cognitive and functional decline. The design of these trials, particularly the exploration of combination therapy, reflects an evolving understanding that targeting multiple pathologies may be necessary for optimal outcomes in AD. While explicit regulatory designations like Fast Track or Orphan Drug for E-2814 itself are not highlighted in the available information, its development within the DIAN-TU framework and in conjunction with an approved therapy like lecanemab suggests a strategic path forward.

In summary, E-2814 has shown clear biological activity against tau pathology in early clinical studies. The ongoing larger trials will be crucial in translating these biomarker effects into tangible clinical benefits for individuals with or at risk for Alzheimer's Disease, potentially positioning E-2814 as a key component in the future multimodal treatment of this devastating neurodegenerative condition.

10. References

1

Works cited

1. Anti-Tau Agent E2814 Shows Impact on Early and Late Tau Biomarkers, Further Supporting Development - NeurologyLive, accessed June 5, 2025, https://www.neurologylive.com/view/anti-tau-agent-e2814-impact-early-late-tau-biomarkers-further-supporting-development
2. Crystal structure of E2814 bound to Tau - PMC, accessed June 5, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11713919/
3. Global Drug Intelligence Database - Synapse, accessed June 5, 2025, https://synapse.patsnap.com/drug/9f642616e25d420f8319ef7eb8100185
4. EISAI PRESENTS LATEST CLINICAL FINDINGS SUGGESTING INHIBITION OF TAU PROPAGATION BY ANTI-MTBR TAU ANTIBODY E2814 AT THE 17TH CLINICAL TRIALS ON ALZHEIMER'S DISEASE CONFERENCE (CTAD) | News Release：2024, accessed June 5, 2025, https://www.eisai.com/news/2024/news202480.html
5. EISAI PRESENTS LATEST CLINICAL FINDINGS SUGGESTING INHIBITION OF TAU PROPAGATION BY ANTI-MTBR TAU ANTIBODY E2814 AT THE 17TH CLINICAL TRIALS ON ALZHEIMER'S DISEASE CONFERENCE (CTAD) - PR Newswire, accessed June 5, 2025, https://www.prnewswire.com/news-releases/eisai-presents-latest-clinical-findings-suggesting-inhibition-of-tau-propagation-by-anti-mtbr-tau-antibody-e2814-at-the-17th-clinical-trials-on-alzheimers-disease-conference-ctad-302292174.html
6. Anti-MTBR (Microtubule Binding Region) Tau Antibody E2814 is Selected on Clinical Study for Dominantly Inherited Alzheimer's Disease By DIAN-TU - Media Center - Eisai, accessed June 5, 2025, https://media-us.eisai.com/anti-mtbr-microtubule-binding-region-tau-antibody-e2814-is-selected-on-clinical-study-for-dominantly-inherited-alzheimers-disease-by-dian-tu
7. Anti-Tau Therapeutic Antibody, E2814, Reduces Early and Late Tau Pathology Biomarkers in Patients with Dominantly-Inherited Alzheimer's Disease (DIAD) - Eisai Medical Information, accessed June 5, 2025, https://www.eisaimedicalinformation.com/-/media/Files/EisaiMedicalInformation/Neurology/Congress-Materials/CTAD-2024/OC4_Wildsmith-et-al---E2814-CTAD24---27OCT2024-FINAL.pdf?hash=e8b856b1-4d01-45f9-974d-b9bc5a806efe
8. Phase 2/3 Study of Tau-Targeting Agent E2814 in Alzheimer Disease Enrolls First Patient, accessed June 5, 2025, https://www.neurologylive.com/view/phase-2-3-study-tau-targeting-agent-e2814-alzheimer-enrolls-first-patient
9. International Alzheimer's clinical trial to test two drugs in ..., accessed June 5, 2025, https://medicine.washu.edu/news/international-alzheimers-clinical-trial-to-test-two-drugs-in-combination/
10. Study E2814-G000-103 - Health Research Authority, accessed June 5, 2025, https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/study-e2814-g000-103/
11. E2814: an anti‐tau therapy engages its CNS target and affects the downstream tangle‐specific biomarker MTBR‐tau243 in Dominantly Inherited Alzheimer's Disease | Request PDF - ResearchGate, accessed June 5, 2025, https://www.researchgate.net/publication/376824870_E2814_an_anti-tau_therapy_engages_its_CNS_target_and_affects_the_downstream_tangle-specific_biomarker_MTBR-tau243_in_Dominantly_Inherited_Alzheimer's_Disease
12. Eisai's Anti-MTBR Tau Antibody E2814 Shows Promise in ..., accessed June 5, 2025, https://trial.medpath.com/news/9feb00003ea5b865/eisai-presents-latest-clinical-findings-suggesting-inhibition-of-tau
13. 15 - YAbS database - The Antibody Society, accessed June 5, 2025, https://db.antibodysociety.org/db0/results_target?page=15&sort=isotype_fc
14. A Study of E2814 With Concurrent Lecanemab Treatment in ..., accessed June 5, 2025, https://www.centerwatch.com/clinical-trials/listings/NCT06602258/a-study-of-e2814-with-concurrent-lecanemab-treatment-in-participants-with-early-alzheimers-disease
15. NCT04971733 - Clinical Research, accessed June 5, 2025, https://www.clinicalresearch.com/en/find-trials/Study/NCT04971733
16. E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease - UCSF Clinical Trials, accessed June 5, 2025, https://clinicaltrials.ucsf.edu/trial/NCT06602258
17. E2814: A Potential Treatment for Alzheimer's Disease - ClinicalTrials.eu, accessed June 5, 2025, https://clinicaltrials.eu/inn/e2814/
18. Specialty Pipeline Includes Drugs for Alzheimer Disease, Hemophilia, NASH, and More, accessed June 5, 2025, https://www.ajmc.com/view/specialty-pipeline-includes-drugs-for-alzheimer-disease-hemophilia-nash-and-more
19. Drugs for Alzheimer Disease, Hemophilia, NASH, and More Pending Approval in Specialty Pipeline, accessed June 5, 2025, https://www.drugtopics.com/view/drugs-for-alzheimer-disease-hemophilia-nash-and-more-pending-approval-in-specialty-pipeline
20. News Release：2021 | Eisai Co., Ltd., accessed June 5, 2025, https://www.eisai.com/news/2021/index.html
21. queryResult - FDA, accessed June 5, 2025, https://www.fda.gov/media/186044/download
22. LATEST DATA ON EISAI'S ALZHEIMER'S DISEASE / DEMENTIA PIPELINE TO BE PRESENTED AT ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2019 | News Release：2019 | Eisai Co., Ltd., accessed June 5, 2025, https://www.eisai.com/news/2019/news201951.html
23. Monoclonal antibodies and aptamers: The future therapeutics for Alzheimer's disease - PMC, accessed June 5, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11252463/
24. LEQEMBI Market Sales Reflect Growing Confidence in Disease-Modifying Alzheimer's Treatments| DelveInsight - GlobeNewswire, accessed June 5, 2025, https://www.globenewswire.com/news-release/2025/03/03/3035903/0/en/LEQEMBI-Market-Sales-Reflect-Growing-Confidence-in-Disease-Modifying-Alzheimer-s-Treatments-DelveInsight.html
25. FDA Approval of Leqembi for Alzheimer's Disease Treatment - DelveInsight, accessed June 5, 2025, https://www.delveinsight.com/blog/leqembi-for-alzheimers-disease-treatment
26. NIA statement on report of lecanemab reducing cognitive decline in Alzheimer's clinical trial, accessed June 5, 2025, https://www.nia.nih.gov/news/nia-statement-report-lecanemab-reducing-cognitive-decline-alzheimers-clinical-trial
27. DIAN-TU SELECTS LECANEMAB AS BACKGROUND ANTI-AMYLOID THERAPY IN CLINICAL TRIAL EVALUATING INVESTIGATIONAL THERAPY TARGETING TAU FOR DOMINANTLY INHERITED ALZHEIMER'S DISEASE | News Release：2021 - Eisai, accessed June 5, 2025, https://www.eisai.com/news/2021/news202184.html
28. Eisai to Present the Latest Research Results, Including Long-Term and Real-Word Data on Lecanemab and Biomarkers for Alzheimer's Disease at the AD/PD™ 2025 Annual Meeting | News Release, accessed June 5, 2025, https://www.eisai.com/news/2025/news202525.html
29. Eisai to present latest Lecanemab findings at AD/PD 2025 - Medical Update Online, accessed June 5, 2025, https://medicalupdateonline.com/2025/03/eisai-to-present-latest-lecanemab-findings-at-ad-pd-2025/
30. EISAI TO PRESENT UPDATED DUAL-ACTING LECANEMAB DATA, RESEARCH ON BLOOD BIOMARKERS FOR PREDICTING PRESENCE OF AMYLOID IN THE BRAIN AND NEW FINDINGS ON THE ANTI-MTBR (MICROTUBULE BINDING REGION) TAU ANTIBODY E2814 AT THE 17TH CLINICAL TRIALS FOR ALZHEIMER'S DISEASE CONFERENCE (CTAD) - PR Newswire, accessed June 5, 2025, https://www.prnewswire.com/news-releases/eisai-to-present-updated-dual-acting-lecanemab-data-research-on-blood-biomarkers-for-predicting-presence-of-amyloid-in-the-brain-and-new-findings-on-the-anti-mtbr-microtubule-binding-region-tau-antibody-e2814-at-the-17th-clinic-302285240.html
31. The U.S. FDA Accepts and Grants Priority Review for EISAI's Biologics License Application of Lecanemab for Early Alzheimer's Disease Under the Accelerated Approval Pathway - Biogen Investor, accessed June 5, 2025, https://investors.biogen.com/news-releases/news-release-details/us-fda-accepts-and-grants-priority-review-eisais-biologics
32. FIRST SUBJECT ENROLLED IN PHASE II/III STUDY OF EISAI'S ANTI-MTBR TAU ANTIBODY E2814 FOR DOMINANTLY INHERITED ALZHEIMER'S DISEASE (DIAD), CONDUCTED BY DIAN-TU | News Release：2022, accessed June 5, 2025, https://www.eisai.com/news/2022/news202205.html
33. Eisai presented findings on anti-MTBR tau antibody E2814 at CTAD - Media Center, accessed June 5, 2025, https://media-us.eisai.com/2024-10-30-EISAI-PRESENTS-LATEST-CLINICAL-FINDINGS-SUGGESTING-INHIBITION-OF-TAU-PROPAGATION-BY-ANTI-MTBR-TAU-ANTIBODY-E2814-AT-THE-17TH-CLINICAL-TRIALS-ON-ALZHEIMERS-DISEASE-CONFERENCE-CTAD
34. Dementia | Key Therapeutic Areas | Eisai Co., Ltd., accessed June 5, 2025, https://www.eisai.com/innovation/research/key_therapeutic_areas/dementia/index.html
35. DIAN EXR Newsletter, accessed June 5, 2025, https://dian.wustl.edu/app/uploads/2022/04/DIAN-EXR-newsletter_Vol-4_Issue-1.pdf
36. An amyloid-β protofibril-selective antibody prevents amyloid formation in a mouse model of Alzheimer's disease | Request PDF - ResearchGate, accessed June 5, 2025, https://www.researchgate.net/publication/26763730_An_amyloid-b_protofibril-selective_antibody_prevents_amyloid_formation_in_a_mouse_model_of_Alzheimer's_disease
37. Emerging Alzheimer's Therapies: AD/PD 2025 Conference - DelveInsight, accessed June 5, 2025, https://www.delveinsight.com/blog/ad-pd-2025-conference-highlights
38. Immune Modulation in Alzheimer's Disease: From Pathogenesis to Immunotherapy - PMC, accessed June 5, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11853524/
39. Eisai Receives Regulatory Review Outcome for Lecanemab as a Treatment for Early Alzheimer's Disease in Australia | News Release：2025, accessed June 5, 2025, https://www.eisai.com/news/2025/news202515.html
40. Error | ClinicalTrials.gov, accessed June 5, 2025, https://clinicaltrials.gov/study/NCT04971733
41. Error | ClinicalTrials.gov, accessed June 5, 2025, https://clinicaltrials.gov/study/NCT05269394
42. accessed January 1, 1970, https://clinicaltrials.gov/study/NCT06602258
43. accessed January 1, 1970, https://classic.clinicaltrials.gov/ct2/show/NCT04971733
44. accessed January 1, 1970, https://classic.clinicaltrials.gov/ct2/show/NCT05269394
45. accessed January 1, 1970, https://classic.clinicaltrials.gov/ct2/show/NCT06602258
46. accessed January 1, 1970, https://www.clinicaltrials.gov/study/NCT04971733
47. accessed January 1, 1970, https://www.clinicaltrials.gov/study/NCT05269394
48. accessed January 1, 1970, https://www.clinicaltrials.gov/study/NCT06602258